trial

A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of Schizophrenia

NCTId NCT00866645
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 240 (estimated)
Sponsored by Shanghai Mental Health Center
Primary completion 2010-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
240 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2009-02
Primary completion
2010-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
HaloperidolSulpiride

Sponsors

Shanghai Mental Health CenterLead Sponsor
Shanghai Hotmed Sciences Co.,LTDCollaborator

Investigators

1
Huafang Li, MD, PhDStudy Director

Sites

5 total
Baoding, ChinaNanjing, ChinaXi'an, ChinaShanghai, ChinaKunming, China

Linked catalysts

1
A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Pa — primary completion2010-07

Facts & assertions

4 sourced
Enrollment
240
Phase
PHASE2,PHASE3
Primary Completion Date
2010-07
Status
COMPLETED
relationships
The graph out of here
drug
Haloperidol
drug
Sulpiride
drug
lead_sponsor
Shanghai Mental Health Center
company
collaborator
Shanghai Hotmed Sciences Co.,LTD
company
indication
Psychomotor Agitation
indication
Schizophrenia
indication
Agitation
indication
investigator
Huafang Li, MD, PhD
person